查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1700171

2032 年泌尿道癌市場預測：按癌症類型、診斷技術、治療、最終用戶和地區進行的全球分析

Urinary Tract Cancer Market Forecasts to 2032 - Global Analysis By Cancer Type (Bladder Cancer, Urethral Cancer and Ureteric & Renal Pelvic Cancer), Diagnostic Technique, Treatment, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球泌尿道癌市場預計在 2025 年達到 37 億美元，到 2032 年將達到 114 億美元，預測期內的複合年成長率為 17.2%。

泌尿道癌是一種發生在負責產生和排泄尿液的器官（例如腎臟、輸尿管、膀胱和尿道）的惡性腫瘤疾病。最常見的是膀胱癌，其次是腎臟癌和輸尿管癌。它通常是由導致細胞不受控制地生長的基因突變引起的，並且常常受到吸煙、長期接觸有毒化學物質、慢性發炎和遺傳易感性等因素的影響。症狀包括尿液中帶血（血尿）、頻尿、排尿疼痛和下腹部不適。

根據美國癌症協會預測，到2022年，將有超過1,800萬美國人患有癌症病史。據估計，2024年美國將診斷出超過200萬例新癌症病例。

免疫療法和標靶治療的採用率增加

泌尿道癌盛行率的不斷上升加速了創新治療方法的採用，特別是免疫療法和標靶治療。這些先進的治療方法透過特異性針對癌細胞同時最大限度地減少對健康組織的損害來提高療效。此外，隨著臨床試驗和新型治療劑研究的持續進行，腫瘤精準醫療的範圍也不斷擴大。對個人化治療策略的日益關注預計將推動泌尿道癌市場的顯著成長。

治療費用高且難以取得

治療泌尿道癌的費用仍然是一個重大障礙，特別是在醫療基礎設施不發達的中低收入國家。免疫療法和分子標靶藥物等先進治療方法價格昂貴，因此大部分患者無法負擔。缺乏廣泛的報銷政策進一步加劇了挑戰，限制了患者獲得新療法的機會。因此，儘管醫學取得了進步，但經濟限制仍然是市場擴張的主要障礙。

新的微創手術技術

外科腫瘤學技術的進步促進了治療泌尿道癌症的微創手術的發展，改善了患者的治療效果。與傳統開放性手術相比，腹腔鏡和機器人輔助手術等技術可以減少術後併發症、縮短住院時間並加快恢復時間。此外，對微創和患者友善治療方法的需求不斷成長，使得這一領域成為市場參與者的有利可圖的成長機會。

標靶治療藥物抗藥性的可能性

泌尿道癌市場面臨的主要挑戰之一是抗藥性的出現，這會顯著降低標靶治療的有效性。隨著時間的推移，癌細胞會形成適應性機制來逃避治療效果，導致病情進展和治療選擇受限。新藥配方成本高昂以及核准流程冗長是額外的障礙，使情況進一步複雜化，並對市場成長和病患生存構成嚴重威脅。

COVID-19的影響：

COVID-19 疫情嚴重影響了癌症的診斷和治療，導致篩檢、選擇性手術和臨床試驗的延遲。封鎖和重新分配醫療資源以管理 COVID-19 病例導致常規腫瘤護理中斷，造成診斷延遲和預後不良。然而，這場大流行加速了遠端醫療和遠端患者監護的採用，改善了諮詢和後續觀察的機會。展望未來，醫療保健提供者將致力於加強癌症護理基礎設施，以防止將來發生類似的中斷。

預計經尿道腫瘤切除術將成為預測期內最大的手術

由於對微創手術解決方案的需求不斷成長，預計經尿道腫瘤切除術領域將在預測期內佔據最大的市場佔有率。 TURT 已被廣泛用於膀胱癌的診斷和治療，具有恢復時間更短、併發症發生率更低、患者預後改善等優點。此外，膀胱癌復發率高，需要再次手術，進一步推動了市場的成長。

放射線治療領域預計將在預測期內實現最高複合年成長率

在先進治療技術需求的推動下，放射治療領域預計將在預測期內達到最高成長率。強度調控放射治療(IMRT) 和影像導航放射治療(IGRT) 等創新技術提高了精確度、減少了對周圍組織的損傷並改善了患者的治療效果。此外，血尿和纖維化等放射線引起的副作用需要後續觀察，這增加了對支持治療的需求。

佔比最大的地區：

在預測期內，由於患者人數迅速增加和醫療保健基礎設施不斷改善，預計亞太地區將佔據最大的市場佔有率。中國、印度和日本等國家泌尿道癌發病率的上升推動了對先進診斷和治療解決方案的需求。此外，大型製藥公司對腫瘤學研究的投資不斷增加以及具有成本效益的學名藥的推出也促進了市場擴張。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這得益於精準醫療的進步、免疫療法的採用率不斷提高以及研究投資的增加。此外，支持快速藥品核准和報銷政策的強力的法律規範正在促進市場成長。由於人口老化和生活方式相關的風險因素，泌尿道癌的盛行率不斷上升，進一步推動了對先進療法的需求。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球泌尿道癌市場（依癌症類型）

  • 膀胱癌
    • 移行細胞癌
    • 鱗狀細胞癌
    • 腺癌
  • 尿道癌
  • 尿道癌/腎盂癌

6. 全球泌尿道癌市場（依診斷技術）

  • 膀胱鏡檢查
  • 經尿道腫瘤切除術
  • 影像檢查
  • 尿液檢查
  • 其他診斷技術

7. 全球泌尿道癌市場：治療

  • 化療
  • 膀胱內治療
  • 放射治療
  • 外科手術
  • 免疫療法

8. 全球泌尿道癌市場（依最終用戶）

  • 醫院
  • 專科診所
  • 門診手術中心
  • 癌症研究所

9. 全球泌尿道癌市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genzyme Corporation
  • IkerChem SL
  • Kyowa Hakko Kirin Co
  • Medical Enzymes AG
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Shionogi & Co., Ltd
  • Spectrum Pharmaceuticals
  • Exact Sciences
  • ImmunityBio, Inc
Product Code: SMRC29074

According to Stratistics MRC, the Global Urinary Tract Cancer Market is accounted for $3.7 billion in 2025 and is expected to reach $11.4 billion by 2032 growing at a CAGR of 17.2% during the forecast period. Urinary Tract Cancer is a condition with malignant growths that develop in the organs responsible for urine production and excretion, including the kidneys, ureters, bladder, and urethra. The most common type is bladder cancer, followed by renal (kidney) cancer and ureteral cancer. It typically arises due to genetic mutations that cause uncontrolled cell growth, often influenced by factors like smoking, prolonged exposure to harmful chemicals, chronic inflammation, and genetic predisposition. Symptoms may include blood in the urine (hematuria), frequent urination, pain during urination, and lower abdominal discomfort.

According to the American Cancer Society, over 18 million Americans were reported to have a history of cancer in the year 2022. It is estimated that over 2 million new cancer cases are expected to be diagnosed in the United States in 2024.

Market Dynamics:

Driver:

Increasing adoption of immunotherapy and targeted therapies

The rising prevalence of urinary tract cancer has accelerated the adoption of innovative treatment approaches, particularly immunotherapy and targeted therapies. These advanced treatment modalities offer improved efficacy by specifically targeting cancer cells while minimizing damage to healthy tissues. Furthermore, ongoing clinical trials and research into novel therapeutic agents continue to expand the scope of precision medicine in oncology. The increasing focus on personalized treatment strategies is expected to drive significant growth in the urinary tract cancer market.

Restraint:

High treatment costs and limited accessibility

The cost of treatment for urinary tract cancer remains a significant barrier, particularly in low- and middle-income countries where healthcare infrastructure is underdeveloped. Advanced therapies such as immunotherapy and targeted drugs come with high price tags, making them unaffordable for a large portion of the patient population. The lack of widespread reimbursement policies further exacerbates the challenge, limiting patient access to novel therapies. As a result, financial constraints continue to be a major impediment to market expansion despite medical advancements.

Opportunity:

Emerging minimally invasive surgical techniques

Technological advancements in surgical oncology have led to the development of minimally invasive procedures for the treatment of urinary tract cancer, improving patient outcomes. Techniques such as laparoscopic and robotic-assisted surgeries offer reduced post-operative complications, shorter hospital stays, and faster recovery times compared to traditional open surgeries. Furthermore, as the demand for less invasive and patient-friendly treatment options rises, this segment presents a lucrative growth opportunity for market players.

Threat:

Potential drug resistance to targeted therapies

One of the major challenges in the urinary tract cancer market is the emergence of drug resistance, which can significantly reduce the effectiveness of targeted therapies. Over time, cancer cells develop adaptive mechanisms that enable them to evade the effects of treatment, leading to disease progression and limited therapeutic options. The high costs and lengthy approval processes for new drug formulations pose additional hurdles, further complicating the landscape posing a significant threat to market growth and patient survival rates.

Covid-19 Impact:

The COVID-19 pandemic had a profound impact on cancer diagnosis and treatment, causing delays in screenings, elective surgeries, and clinical trials. Lockdowns and healthcare resource reallocation toward managing COVID-19 cases led to disruptions in routine oncology care, resulting in late-stage diagnoses and poorer prognoses. However, the pandemic also accelerated the adoption of telemedicine and remote patient monitoring, improving access to consultations and follow-ups. Moving forward, healthcare providers are focusing on strengthening cancer care infrastructure to prevent similar disruptions in the future.

The transurethral resection of tumor segment is expected to be the largest during the forecast period

The transurethral resection of tumor segment is expected to account for the largest market share during the forecast period owing to driving demand for minimally invasive surgical solutions. TURT is widely adopted for diagnosing and treating bladder cancer, offering advantages such as reduced recovery time, lower complication rates, and improved patient outcomes. Moreover, high recurrence rates of bladder cancer necessitate repeat procedures, further boosting market growth.

The radiation therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the radiation therapy segment is predicted to witness the highest growth rate driving demand for advanced treatment technologies. Innovations like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) enhance precision, reducing damage to surrounding tissues and improving patient outcomes. Moreover, radiation-induced side effects, such as hematuria and fibrosis, necessitate follow-up care, boosting demand for supportive treatments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its rapidly expanding patient population and improving healthcare infrastructure. The rising incidence of urinary tract cancer in countries like China, India, and Japan is driving the demand for advanced diagnostic and treatment solutions. Additionally, the growing presence of key pharmaceutical companies investing in oncology research and the introduction of cost-effective generic drugs are contributing to market expansion.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by advancements in precision medicine, rising adoption of immunotherapy, and increasing research investments. Additionally, a strong regulatory framework supporting fast-track drug approvals and reimbursement policies is boosting market growth. The increasing prevalence of urinary tract cancer due to aging populations and lifestyle-related risk factors is further driving demand for advanced therapies.

Key players in the market

Some of the key players in Urinary Tract Cancer Market include Amgen Inc., AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, IkerChem S.L, Kyowa Hakko Kirin Co, Medical Enzymes AG, Merck & Co Inc, Novartis AG , Pfizer Inc, Shionogi & Co., Ltd, Spectrum Pharmaceuticals, Exact Sciences and ImmunityBio, Inc.

Key Developments:

In March 2024, Exact Sciences launched Cxbladder Trio, a non-invasive urine-based genomic test for detecting upper tract urothelial cancer (UTUC). The test combines mRNA biomarkers and clinical risk factors, offering 92% sensitivity in early-stage diagnosis, per clinical validation studies.

In April 2024, ImmunityBio, Inc. announced that the U.S. FDA approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This approval introduces a novel immunotherapy option enhancing treatment outcomes for bladder cancer patients.

Cancer Types Covered:

  • Bladder Cancer
  • Urethral Cancer
  • Ureteric & Renal Pelvic Cancer

Diagnostic Techniques Covered:

  • Cystoscopy
  • Transurethral Resection of Tumor
  • Imaging Tests
  • Urine Analyses
  • Other Diagnostic Techniques

Treatments Covered:

  • Chemotherapy
  • Intravesical Therapy
  • Radiation Therapy
  • Surgery
  • Immunotherapy

End Users Covered:

  • Hospitals
  • Speciality Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Urinary Tract Cancer Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Bladder Cancer
    • 5.2.1 Transitional Cell Carcinoma
    • 5.2.2 Squamous Cell Carcinoma
    • 5.2.3 Adenocarcinoma
  • 5.3 Urethral Cancer
  • 5.4 Ureteric & Renal Pelvic Cancer

6 Global Urinary Tract Cancer Market, By Diagnostic Technique

  • 6.1 Introduction
  • 6.2 Cystoscopy
  • 6.3 Transurethral Resection of Tumor
  • 6.4 Imaging Tests
  • 6.5 Urine Analyses
  • 6.6 Other Diagnostic Techniques

7 Global Urinary Tract Cancer Market, By Treatment

  • 7.1 Introduction
  • 7.2 Chemotherapy
  • 7.3 Intravesical Therapy
  • 7.4 Radiation Therapy
  • 7.5 Surgery
  • 7.6 Immunotherapy

8 Global Urinary Tract Cancer Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Speciality Clinics
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Cancer Research Institutes

9 Global Urinary Tract Cancer Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Amgen Inc.
  • 11.2 AstraZeneca
  • 11.3 Boehringer Ingelheim GmbH
  • 11.4 Bristol-Myers Squibb Company
  • 11.5 Eli Lilly and Company
  • 11.6 F. Hoffmann-La Roche Ltd
  • 11.7 Genzyme Corporation
  • 11.8 IkerChem S.L
  • 11.9 Kyowa Hakko Kirin Co
  • 11.10 Medical Enzymes AG
  • 11.11 Merck & Co Inc
  • 11.12 Novartis AG
  • 11.13 Pfizer Inc
  • 11.14 Shionogi & Co., Ltd
  • 11.15 Spectrum Pharmaceuticals
  • 11.16 Exact Sciences
  • 11.17 ImmunityBio, Inc

List of Tables

  • Table 1 Global Urinary Tract Cancer Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Urinary Tract Cancer Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 3 Global Urinary Tract Cancer Market Outlook, By Bladder Cancer (2024-2032) ($MN)
  • Table 4 Global Urinary Tract Cancer Market Outlook, By Transitional Cell Carcinoma (2024-2032) ($MN)
  • Table 5 Global Urinary Tract Cancer Market Outlook, By Squamous Cell Carcinoma (2024-2032) ($MN)
  • Table 6 Global Urinary Tract Cancer Market Outlook, By Adenocarcinoma (2024-2032) ($MN)
  • Table 7 Global Urinary Tract Cancer Market Outlook, By Urethral Cancer (2024-2032) ($MN)
  • Table 8 Global Urinary Tract Cancer Market Outlook, By Ureteric & Renal Pelvic Cancer (2024-2032) ($MN)
  • Table 9 Global Urinary Tract Cancer Market Outlook, By Diagnostic Technique (2024-2032) ($MN)
  • Table 10 Global Urinary Tract Cancer Market Outlook, By Cystoscopy (2024-2032) ($MN)
  • Table 11 Global Urinary Tract Cancer Market Outlook, By Transurethral Resection of Tumor (2024-2032) ($MN)
  • Table 12 Global Urinary Tract Cancer Market Outlook, By Imaging Tests (2024-2032) ($MN)
  • Table 13 Global Urinary Tract Cancer Market Outlook, By Urine Analyses (2024-2032) ($MN)
  • Table 14 Global Urinary Tract Cancer Market Outlook, By Other Diagnostic Techniques (2024-2032) ($MN)
  • Table 15 Global Urinary Tract Cancer Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 16 Global Urinary Tract Cancer Market Outlook, By Chemotherapy (2024-2032) ($MN)
  • Table 17 Global Urinary Tract Cancer Market Outlook, By Intravesical Therapy (2024-2032) ($MN)
  • Table 18 Global Urinary Tract Cancer Market Outlook, By Radiation Therapy (2024-2032) ($MN)
  • Table 19 Global Urinary Tract Cancer Market Outlook, By Surgery (2024-2032) ($MN)
  • Table 20 Global Urinary Tract Cancer Market Outlook, By Immunotherapy (2024-2032) ($MN)
  • Table 21 Global Urinary Tract Cancer Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Urinary Tract Cancer Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 23 Global Urinary Tract Cancer Market Outlook, By Speciality Clinics (2024-2032) ($MN)
  • Table 24 Global Urinary Tract Cancer Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 25 Global Urinary Tract Cancer Market Outlook, By Cancer Research Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.